Hardy; Britta

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hardy; Britta.The latest application filed is for "compositions and methods for inducing angiogenesis".

Company Profile

0.12.13

Hardy; Britta - Tel-Aviv N/A IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and methods for inducing angiogenesis Grant 8,741,843 - Hardy , et al. June 3, 2	2014-06-03
Compositions And Methods For Inducing Angiogenesis App 20120219498 - HARDY; BRITTA ; et al.	2012-08-30
Compositions and methods for inducing angiogenesis Grant 8,227,413 - Hardy , et al. July 24, 2	2012-07-24
Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency Grant 7,981,416 - Hardy , et al. July 19, 2	2011-07-19
Compositions and Methods for Inducing Angiogenesis App 20100322856 - Hardy; Britta ; et al.	2010-12-23
Peptide useful in immunomodulation Grant 7,745,397 - Hardy , et al. June 29, 2	2010-06-29
Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases Grant 7,695,715 - Hardy , et al. April 13, 2	2010-04-13
Humanized Immunomodulatory Monoclonal Antibodies For The Treatment Of Neoplastic Disease Or Immunodeficiency App 20090263386 - Hardy; Britta ; et al.	2009-10-22
Angiogenic peptides and uses thereof App 20090163405 - Hardy; Britta ; et al.	2009-06-25
Use Of Bat Monoclonal Antibody For Immunotherapy App 20090123413 - Hardy; Britta ; et al.	2009-05-14
Human immunomodulatory monoclonal antibodies for the treatment of cancer Grant 7,524,498 - Hardy , et al. April 28, 2	2009-04-28
Angiogenic peptides and uses thereof Grant 7,473,682 - Hardy , et al. January 6, 2	2009-01-06
Peptide Useful In Immunomodulation App 20080175855 - Hardy; Britta ; et al.	2008-07-24
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency Grant 7,332,582 - Hardy , et al. February 19, 2	2008-02-19
Peptide useful in immunomodulation Grant 7,329,639 - Hardy , et al. February 12, 2	2008-02-12
Humanized Immunomodulatory Monoclonal Antibodies For The Treatment Of Neoplastic Disease Or Immunodeficiency App 20080025980 - Hardy; Britta ; et al.	2008-01-31
Angiogenic peptides and uses thereof App 20070082849 - Hardy; Britta ; et al.	2007-04-12
Peptide useful in immunomodulation Grant 7,122,372 - Hardy , et al. October 17, 2	2006-10-17
Peptide useful in immunomodulation App 20060210573 - Hardy; Britta ; et al.	2006-09-21
Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases App 20060099209 - Hardy; Britta ; et al.	2006-05-11
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency App 20050180969 - Hardy, Britta ; et al.	2005-08-18
Peptide useful in immunomodulation App 20050003397 - Hardy, Britta ; et al.	2005-01-06
Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases App 20030026800 - Hardy, Britta ; et al.	2003-02-06
Immuno-stimulatory monoclonal antibodies Grant 5,897,862 - Hardy , et al. April 27, 1	1999-04-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.